Abstract
A sensitive and reproducible high performance liquid chromatography (HPLC) method has been developed and validated for the quantification of metolazone in human plasma, after solid phase extraction (SPE). A Good resolution was achieved on a reverse-phase LichroCART Purospher® C18 column using the mobile phase acetonitrile– 0.5% triethylamine (35:65) in isocratic elution with a total run time of 15 min. The analyte, metolazone, was detected by using high performance liquid chromatography with the support of photo diode array detector. Limit of detection and Lower limit of quantification was found to be 1 and 2.5 ng/mL. The present method was successfully applied in the pharmacokinetic study of metolazone in human plasma.
Highlights
This work deals with the studies carried out by the writer in this laboratory for the past one year on the development of analytical method used for the estimation of Metolazone in biological fluids and Bioequivalence studies on Metolazone tablets
Limited methods have been reported for high performance liquid chromatography (HPLC) and LC-MS
Under the proposed assay condition internal standard and metolazone had a retention time of 7.97 and 10.36 min, respectively, rest of the peaks were due to the plasma components
Summary
This work deals with the studies carried out by the writer in this laboratory for the past one year on the development of analytical method used for the estimation of Metolazone in biological fluids and Bioequivalence studies on Metolazone tablets. A proximal action of Metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies. Doi:10.4172/jbb.1000024 dards (HQC) were prepared by spiking drup free plasma with metolazone to give solutions containing 6.0, 50.0, and 500.0, 22.5 ng/mL, respectively. They were stored at -20±2°C till analysed.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
